97 results about "TB - Tuberculosis" patented technology

The invention discloses a variable splicing marker for tuberculosis diagnosis, a screening method and application, and relates to the technical field of marker screening, and the technical key points are as follows: the variable splicing marker is AIM2-Intron3-IR; by combining bioinformatics analysis, in-vitro experiments and clinical queue verification analysis of a large amount of high-throughput sequencing data, variable splicing markers closely related to tuberculosis are mined and determined, and a high-efficiency new tool is provided for tuberculosis diagnosis.

The invention belongs to the field of medical treatment, and provides an accurate tuberculosis detection system based on ultrasonic intervention, which comprises an ultrasonic probe used for acquiring an ultrasonic image of a target area; the three-dimensional modeling part is used for constructing a three-dimensional model of a target area based on the ultrasonic image and the spatial position information of the ultrasonic probe; the ultrasonic guiding part is connected with the three-dimensional modeling part and used for calculating an optimal detection path based on the three-dimensional model and the real-time position of the ultrasonic probe and guiding the operator to obtain a second ultrasonic image through the intercostal space; and the detection module is connected with the ultrasonic guide part and is used for accurately detecting tuberculosis based on the second ultrasonic image.

The invention discloses a variable splicing marker for predicting the progress of tuberculosis and application thereof, and relates to the technical field of markers for predicting the progress of tuberculosis and application thereof, and the technical key points are that the variable splicing markers are DNASE1L2-IR and PHF11-IR, and the markers are used for predicting the progress of tuberculosis; the variable splicing markers closely related to latent tuberculosis and progressive tuberculosis are mined and determined by combining bioinformatics analysis and in vitro experiments of a large amount of high-throughput sequencing data, and a high-efficiency new tool is provided for predicting the progress of tuberculosis.

The invention discloses a tuberculosis report case recent propagation prediction method based on machine learning, and belongs to the technical field of report case propagation prediction method.The tuberculosis report case recent propagation prediction method includes the steps that genome information of yang-cultivating patients is collected, the patient propagation relation is researched and judged according to bacterial genetic correlation, and a feature library is constructed; standardized feature engineering for performing one-hot coding on multi-classification features is adopted, whether a genome is clustered or not is used as a dichotomy result variable, a trained classification model is adopted to classify ten-fold cross validation data of a training set, a classification result is output, after tuning is completed, a test set is imported into the model, and according to a prediction result and an actual result of the model, a test result is obtained. And evaluating the final performance of the model through the confusion matrix, the use accuracy, the precision rate, the recall rate, the F1 score and the AUC index.

The invention belongs to the technical field of biology, and particularly relates to a biomarker for differential diagnosis and prognosis of severe tuberculosis and application of the biomarker. According to the invention, the expression level of sCD27 in patients with severe pulmonary tuberculosis is obviously increased; when sCD27 in a biological sample of a subject is greater than or equal to 95097 pg / ml, the subject is diagnosed as severe pulmonary tuberculosis; the area under the curve is 0.7674 (95% CI is equal to 0.6158 to 0.9190); the sensitivity is 45.45%, and the specificity is 88.24%. When the sCD27 level is higher than 158510pg / ml, the prognosis is poor, and a subject has a death risk; the area under the curve is 0.7465 (95% CI is equal to 0.5756 to 0.9175); the sensitivity is 57.14%, and the specificity is 83.87%. The sCD27 as a biomarker for distinguishing severe and non-severe pulmonary tuberculosis patients and predicting prognosis effects of the pulmonary tuberculosis patients has relatively high accuracy and specificity, and is helpful for determining clinical diagnosis and treatment schemes.

The invention discloses a pulmonary tuberculosis focus map segmentation system based on symmetric similarity and dynamic sample amplification, which comprises a sternum suppression network module, an entropy-driven sample number dynamic amplification module, a pulmonary tuberculosis focus detection module and a sternum suppression network module, and is used for removing a sternum image in a chest X-ray map; the entropy-driven sample dynamic amplification module is used for carrying out dynamic amplification on the number of sample images based on the complexity of the image and the existing training state of the model for a single image; specifically, for each image, an information entropy is calculated for probability distribution output by a model of each training round; in the early stage of training, the number of training image samples is amplified slightly, and the number of amplified samples is increased along with model training; and the pulmonary tuberculosis focus detection module is used for designing a pulmonary tuberculosis focus detection network model by using the target detector and the symmetric similarity of the pulmonary tuberculosis images, and segmenting a tuberculosis focus map from the X-ray map.

The present invention discloses a kit for diagnosing active tuberculosis. The kit includes a substance for detecting IFIT3 protein. Compared with healthy people and latent tuberculosis infected people, the expression of IFIT3 gene in PBMCs of active tuberculosis patients is significantly increased; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from latent tuberculosis infected people; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from healthy people. Therefore, IFIT3 protein and / or IFIT3 gene can be used as a marker to diagnose active tuberculosis. The present invention has great application value.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The invention relates to tuberculosis early warning, in particular to an early warning management method for suspected tuberculosis cases, which comprises the following steps of: carrying out standardized coding system design on a pulmonary tuberculosis examination institution, a jurisdiction fixed-point institution, a jurisdiction fixed-point institution department, a jurisdiction fixed-point institution doctor and an early warning management system workstation, and carrying out warehousing management on related information; setting a database table and a corresponding index; determining a contrast relationship between the pulmonary tuberculosis examination institution and the jurisdiction fixed-point institution, and a logic relationship between a jurisdiction fixed-point institution department to which a jurisdiction fixed-point institution doctor belongs and an early warning management system workstation to which the jurisdiction fixed-point institution department belongs; when the pulmonary tuberculosis examination institution judges that a suspected tuberculosis case appears, early warning bubbles are pushed through an early warning management system work station to remind a designated jurisdiction fixed-point institution department and a designated jurisdiction fixed-point institution doctor, and whole-process state management is carried out; according to the technical scheme provided by the invention, the defect that efficient early warning management is difficult to carry out on suspected tuberculosis cases in the prior art can be effectively overcome.

According to the invention, 23 key miRNAs are identified in patients with liver injury caused by taking antituberculous drugs. Compared with patients who cannot cause liver injury by taking antituberculous drugs, the miRNAs are obviously differentially expressed in the patients who cannot cause liver injury by taking antituberculous drugs. Furthermore, five miRNAs are selected from the key miRNAs to construct a diagnosis model for drug-induced liver injury caused by tuberculosis and antituberculosis drugs. The model can accurately diagnose tuberculosis, and also can accurately diagnose drug-induced liver injury caused by antituberculosis drugs.

Methods for treating tuberculosis are provided.

The present disclosure provides small molecule anti-tuberculosis agents and pharmaceutical compositions comprising the anti-tuberculosis agents. The disclosure further provides a method of treating tuberculosis, including drug-resistant tuberculosis, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the anti-tuberculosis agent.

A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

The invention relates to a compound for preventing or treating tuberculosis (TB) or an acceptable salt of the compound, and the compound is shown as a general formula (I).

The application provides a biomarker composition for diagnosing tuberculosis, the biomarker composition screened by the application can be used for diagnosing tuberculosis, and the area under the ROC curve (AUC) of the model for diagnosing tuberculosis is greater than 0.9, when the cut-off value (diagnosis threshold value) is 0.696, the sensitivity and specificity of diagnosis are both greater than 80%.

The invention discloses a method for constructing a model for performing treatment outcome grouping on AIDS (acquired immune deficiency syndrome) and phthisis patients and application of the method. The invention provides a method for constructing a model for performing anti-tuberculosis treatment outcome grouping on AIDS (Acquired Immune Deficiency Syndrome) and pulmonary tuberculosis patients, which comprises the following steps of: taking five specific index data of known AIDS and pulmonary tuberculosis patient groups with different anti-tuberculosis treatment outcomes as training samples; training a model for performing anti-tuberculosis treatment outcome grouping on the AIDS and pulmonary tuberculosis patients; the five specific indexes are CAR, extrapulmonary tuberculosis, other pulmonary infections, lung cavities and CD4 + T lymphocyte count. According to the method, clinical doctors can quickly identify AIDS and tuberculosis patients with high treatment failure risk, personalized management is carried out on the AIDS and tuberculosis patients, the method is of great importance to reduction of the occurrence rate of retreatment and drug-resistant tuberculosis, and a new strategy is provided for precise treatment.

The invention discloses a spinal tuberculosis auxiliary diagnosis method and system, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: acquiring a spinal tuberculosis DR image to be diagnosed; performing a preprocessing operation on the DR image to reduce image noise and enhance a spine structure contrast; inputting the preprocessed DR image into a pre-trained spinal tuberculosis classification model to obtain prediction probability distribution and confidence evaluation of the spinal tuberculosis physical classification; inputting the preprocessed DR image into a pre-trained focus detection model to obtain spatial position positioning information of the spinal tuberculosis focus; and integrating the prediction probability distribution, confidence evaluation and spatial position positioning information to generate an auxiliary diagnosis report. Under the condition of low-quality DR images in primary hospitals, primary doctors can be assisted in improving the diagnosis accuracy and positioning precision of early spinal tuberculosis lesions.

The invention discloses a three-gene combination, a primer probe set and a system for qPCR (quantitative polymerase chain reaction) rapid screening of tuberculosis progression risk and application of the three-gene combination, the primer probe set and the system. The method comprises the following steps: firstly, screening out candidate genes APOL1, C1QC and SOCS1 which are stable across time windows and have high prediction performance; then a three-gene combination scoring you model (PRI3) composed of APOL1, C1QC and SOCS1 is constructed and used for predicting the risk that a latent tuberculosis infected individual progresses into active tuberculosis within a set time window; the method comprises the following steps of: firstly, selecting a reference model (RISK6, Sweeney3, Gliddon4 and BATF2), then performing performance verification in an independent verification queue, and comparing with the existing reference model (RISK6, Sweeney3, Gliddon4 and BATF2), and the result shows that the scoring model disclosed by the invention can keep stable performance in adult population and multiple time windows (such as 0-6 months, 0-12 months and 0-24 months). The scheme of the invention is suitable for crowd screening, disease early warning and individualized intervention decision.

The invention provides an abdominal tuberculosis image processing method, and relates to the technical field of image processing and medical image analysis. The method comprises the following specific steps: collecting an abdominal tuberculosis image, making a data set, preprocessing the image, establishing a multi-scale convolution module, establishing a multi-scale pooling module, optimizing a feature fusion module, establishing a classification prediction module, constructing an abdominal tuberculosis image processing model, and training and detecting the abdominal tuberculosis image processing model. According to the method, an adaptive enhancement mechanism and a noise suppression strategy are introduced to pre-process an image data set, a multi-scale convolution module and a pooling module are designed to realize multi-scale feature extraction and fusion, low-frequency and high-frequency information fusion and an adaptive weighting mechanism are adopted to optimize image feature processing, and a plurality of modules act synergistically to realize multi-scale feature extraction and fusion. The processing efficiency and the classification precision of the abdominal tuberculosis image are remarkably improved, and particularly, the method shows relatively high robustness and adaptability in image analysis of different tuberculosis change stages.

The invention relates to a T cell intracellular factor composition and application thereof, the T cell intracellular factor composition is selected from multiple of CCL3, CCL4, IFN gamma and TNFa, and the expression levels of the CCL3, the CCL4, the IFN gamma and the TNFa in peripheral blood of active tuberculosis patients are obviously different. As the expression levels in the peripheral blood of the active tuberculosis patient are obviously different, different stages and health states of tuberculosis can be accurately distinguished, the accuracy and specificity of diagnosis are obviously improved, and a reliable basis is provided for clinical diagnosis.

The application discloses a combination of three lncRNA markers for screening tuberculosis patients and application thereof. The application provides application of a substance for detecting marker 1, a substance for detecting marker 2 and a substance for detecting marker 3 in preparation of a kit for screening tuberculosis patients. The application also provides application of the marker 1, the marker 2 and the marker 3 as combined markers in development of a kit for screening tuberculosis patients. The marker 1 is lncRNA 046173 or a characteristic fragment of the lncRNA 046173. The marker 2 is lncRNA PRDM7-1:2 or a characteristic fragment of the lncRNA PRDM7-1:2. The marker 3 is lncRNA CHI3L1-2:3 or a characteristic fragment of the lncRNA CHI3L1-2:3. The three lncRNAs have more excellent performance as combined diagnostic markers. The application is very important for rapid diagnosis and early treatment of tuberculosis.

Provided is a compound for preventing or treating tuberculosis (TB) or an acceptable salt thereof, the compound being represented by general formula (I).

The present invention discloses a group of fusion proteins for assisting the diagnosis of tuberculosis, which include 38KD-MPT32-MPT64, CFP10-Mtb81-EspC and Ag85B-HBHA fusion proteins. The above fusion protein combination can be used for the detection of antigen-specific tuberculosis antibodies in the body fluids of tuberculosis patients, and has the characteristics of high sensitivity, specificity and low cost for assisting the diagnosis of tuberculosis. At the same time, the new antigen combination provided by the present invention can provide a scientific reference for the diagnosis and treatment of tuberculosis.

The invention belongs to the technical field of sample split charging, and particularly relates to tuberculosis sample automatic split charging and label printing equipment which comprises a supporting base and a split charging sleeve box, a split charging table is fixedly connected to the supporting base, a conveying mechanism is arranged on the split charging table, and a first mounting plate and a second mounting plate are fixedly connected to the split charging table; the first mounting plate and the second mounting plate are symmetrically arranged, the first mounting plate and the second mounting plate are located on the two sides of the sub-packaging table respectively, three sub-packaging assemblies which are symmetrically arranged are arranged between the first mounting plate and the second mounting plate, and each sub-packaging assembly comprises two sub-packaging suites which are symmetrically arranged. According to the tuberculosis sample subpackaging device, the contact time of medical workers and tuberculosis samples can be shortened, the infection risk is reduced, the specialized medical workers do not need to discriminate and subpackage the samples in the subpackaging process, meanwhile, the sample leakage harm caused by misoperation of operators can be reduced, and the safety coefficient of tuberculosis sample subpackaging and label printing is improved.

The invention discloses a lipid biomarker for tuberculosis-coronary heart disease co-diagnosis and application of the lipid biomarker. Lipid is any one or a combination of LPC (O-22: 1), PI (10: 016: 0) or PC (10: 018: 0). The lipid biomarker provided by the invention can be used for early diagnosis of tuberculosis-coronary heart disease patients of tuberculosis patients, and may become an intervention target for preventing tuberculosis from developing into tuberculosis-coronary heart disease co-diseases.

This invention relates to the field of biological sample preservation technology, specifically to a room-temperature preservation solution for bacterial RNA from sputum samples of tuberculosis patients. Each 100 mL of the RNA preservation solution comprises the following ingredients: 2-5 g tris(hydroxymethyl)aminomethane, 0.5-1.3 g mucin digester, 20-30 g guanidine isothiocyanate, 0.1-0.3 g hexadecylpyridine chloride, 0.5-1.2 g ethylhexene dicysteine, 20-40 mL fixative, 1-5 g stabilizer, 0.1-0.5 g inorganic salt, 0.3-0.6 g surfactant, and 0.1-0.5 g preservative. The preservation solution provided by this invention can effectively liquefy sputum samples at room temperature, meeting the requirements for long-distance sample transportation. The RNA quality of sputum samples treated with the preservation solution of this invention is suitable for various subsequent molecular detection methods, possessing significant application value and promising prospects for widespread application.

A chrysin derivative and a composition for a treatment of tuberculosis containing the same are provided. In detail, a chrysin derivative compound represented by chemical formula 1,or a salt thereof, and a composition for a treatment of tuberculosis and inflammation containing the same as an active ingredient are provided. In chemical formula 1, at least one of R1 and R2 is hydrogen, and the other is a C1-6 hydroxyalkyl group or a C1-10 alkenyl group unsubstituted or substituted with one or more C1-10 alkyl groups

The invention relates to the technical field of biological medicines, and discloses application of an IGF1R (Insulin-like Growth Factor 1 Receptor) gene as an anti-tuberculosis target spot in treatment and / or diagnosis of tuberculosis. The IGF1R gene is related to the susceptibility of tuberculosis. The IGF1R gene is used for regulating a tumor-related pathway and a PI3K-Akt signal pathway, so that host-oriented anti-tuberculosis is realized. BEAS-2B cells are stimulated through PPD, it is proved that the IGF1R gene has susceptibility correlation with TB, the correlation between the IGF1R gene and a tumor-related pathway and a PI3K-Akt signal pathway and related key functional genes are determined, a new thought is provided for research on TB morbidity and tuberculosis susceptibility, and a foundation is laid for the IGF1R gene serving as a new target in TB diagnosis and treatment.

A tuberculosis detection kit includes diagnostic reagents for 17 serum metabolites of patients with tuberculosis, the detecting reagent being used for quantitative detection of the 17 serum metabolites of the patients with tuberculosis, the 17 serum metabolites comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0 / 14:0 / 0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1 / 12:0), Raffinose, LysoPC(20:1(11Z) / 0:0), LysoPC(22:4(7Z,10Z,13Z,16Z) / 0:0), PC(18:1(9Z)e / 2:0), Torvoside G(TG(15:0 / 15:0 / 15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0 / 16:0), NADP, TG(20:0 / 20:0 / 20:1(11Z)).